A study of Dato-DXd in Chinese Patients with Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

Study identifier:D9266C00001

ClinicalTrials.gov identifier:NCT05460273

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advanced Non-small-cell Lung Cancer, Triple-negative Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Urothelial Cancer, and Other Solid Tumours (TROPION-PanTumor02)

Medical condition

Carcinoma, Non-Small-Cell Lung

Phase

Phase 1/2

Healthy volunteers

No

Study drug

Datopotamab Deruxtecan (Dato-DXd)

Sex

All

Actual Enrollment

119

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 11 Jul 2022
Estimated Primary Completion Date: 18 Dec 2023
Estimated Study Completion Date: 23 Jun 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Daiichi Sankyo, Inc.

Inclusion and exclusion criteria